Commentary|Videos|August 12, 2024

Potential Advancements in Patient Centricity

In the fourth and final part of this video interview, Vincent Keunen, founder & CEO of Andaman7 looks forward and highlights some potential advancements with the use of AI.

ACT: What are some patient-centric advancements you are looking forward to seeing in the next five years?

Keunen: The big thing today is clearly AI (artificial intelligence), right? Everybody's talking about it. There's probably too much talk, and there's a hype, obviously, like always, but it's also a real improvement. It really does help for some features. For example, what I’ve personally used AI for is to explain to me a document with information coming from a specialist doctor, and it has medical-specific terms—very hard to understand for patients, and so the AI can explain that in a simpler manner. AI can also summarize. For example, I put a whole document in for a checkup that I did one year ago, just a checkup on heart condition and there were two pages of information, and the AI summarized it by saying, “There is no problem, next checkup in one year,” which was perfect. Two sentences. It's just what I need in my case.

It can also help translate in different languages. That's important if you go abroad on vacation, or if you work abroad for some of the time. AI is clearly a big thing, and I think it will help a lot. Of course, there's all kinds of privacy questions and issues to solve, and quality issues also, all of that is important. Some things that we already know, like the mobile phone and the internet, they don't see innovations as much today, but they are pretty powerful technology for creating communities of patients to help them work together and to help the research industry. Maybe the three main things is mobile phone, internet, and AI put together—that will probably be a very interesting combination of technologies to help patients and then help providers and research also in their endeavor to help patients.


Related to this article

© C Davids/peopleimages.com - © C Davids/peopleimages.com - stock.adobe.com
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Why Seizure Counts Alone Can't Define Success in Epilepsy Trials
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why the full burden of developmental and epileptic encephalopathies extends far beyond clinical symptoms—and why endpoints must reflect what families are actually hoping for.
What It Actually Means to Embed the Patient Voice in Trial Design
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why genuine patient partnership begins before the protocol is written—and what it looks like when patients and caregivers tell you a trial was designed with them in mind.